Atrial septal defect medical therapy for stroke: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Aspirin has been found to decrease the incidence of recurrent stroke and transient ischemic attacks in patients with [[atrial septal defect]] and [[patent foramen ovale]] | Aspirin has been found to decrease the incidence of recurrent stroke and transient ischemic attacks in patients with [[atrial septal defect]] and [[patent foramen ovale]]<ref name="pmid11742048">{{cite journal| author=Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G et al.| title=Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 24 | pages= 1740-6 | pmid=11742048 | doi=10.1056/NEJMoa011503 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11742048 }} </ref>. The 'American Heart Association' guidelines support the utilization of sustained warfarin therapy in high-risk atrial septal defect patients </ref> American College of Chest Physicians recommends utilizing antiplatelet therapy for some [[patent foramen ovale]] patients.<ref name="pmid18574275">{{cite journal| author=Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of Chest Physicians| title=Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | journal=Chest | year= 2008 | volume= 133 | issue= 6 Suppl | pages= 630S-669S | pmid=18574275 | doi=10.1378/chest.08-0720 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18574275 }} </ref> | ||
==Medical therapy for stroke== | ==Medical therapy for stroke== | ||
Revision as of 18:54, 1 September 2011
|
Atrial Septal Defect Microchapters | |
|
Treatment | |
|---|---|
|
Surgery | |
|
| |
|
Special Scenarios | |
|
Case Studies | |
|
Atrial septal defect medical therapy for stroke On the Web | |
|
American Roentgen Ray Society Images of Atrial septal defect medical therapy for stroke | |
|
Risk calculators and risk factors for Atrial septal defect medical therapy for stroke | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [[2]]; Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [[4]]
Overview
Aspirin has been found to decrease the incidence of recurrent stroke and transient ischemic attacks in patients with atrial septal defect and patent foramen ovale[1]. The 'American Heart Association' guidelines support the utilization of sustained warfarin therapy in high-risk atrial septal defect patients </ref> American College of Chest Physicians recommends utilizing antiplatelet therapy for some patent foramen ovale patients.[2]
Medical therapy for stroke
- Researchers have investigated the justification for aspirin therapy in patients with atrial septal defects and patent foramen ovale, who have had stroke or a transient ischemic attack.[1]
- Aspirin therapy was observed to have an effective role in reducing the incidence of recurrent stroke after four years.[1]
- Another pharmacologic intervention study indicated that aspirin and warfarin therapy were effective [3]
- The AHA guidelines support the utilization of sustained warfarin therapy in high-risk atrial septal defect patients. [4] American College of Chest Physicians recommends utilizing antiplatelet therapy for some patent foramen ovale patients.[2] Anticoagulation therapy for patent foramen ovale patients, specifically ones with pulmonary embolus or deep vein thrombosis.
See also
References
- ↑ 1.0 1.1 1.2 Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G; et al. (2001). "Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both". N Engl J Med. 345 (24): 1740–6. doi:10.1056/NEJMoa011503. PMID 11742048.
- ↑ 2.0 2.1 Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of Chest Physicians (2008). "Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 630S–669S. doi:10.1378/chest.08-0720. PMID 18574275.
- ↑ Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, PFO in Cryptogenic Stroke Study (PICSS) Investigators (2002). "Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study". Circulation. 105 (22): 2625–31. PMID 12045168.
- ↑ Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC; et al. (2011). "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association". Stroke. 42 (1): 227–76. doi:10.1161/STR.0b013e3181f7d043. PMID 20966421.